Neos Therapeutics names new CFO
This article was originally published in Scrip
Neos Therapeutics, a specialty pharmaceutical company developing drug delivery technologies and controlled-release products to treat attention-deficit hyperactivity disorder (ADHD), has named Richard I Eisenstadt chief financial officer – effective 22 May. Before joining Dallas and Fort Worth, Texas-based Neos, Mr Eisenstadt was chief financial officer at ArborGen; a company which develops technologies to improve the productivity of trees.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.